Top 10 Rotigotine (Neupro) Generic Manufacturers in Brazil
The Brazilian pharmaceutical market has been experiencing significant growth, driven by an increasing prevalence of chronic diseases and an aging population. In 2021, the Brazilian pharmaceutical market was valued at approximately $40 billion, with a projected compound annual growth rate (CAGR) of 8% through 2026. Rotigotine, marketed under the brand name Neupro, is a transdermal patch used primarily in the treatment of Parkinson’s disease and restless legs syndrome. With an expanding generics market, Brazil is poised to become a key player in the production of rotigotine generics, offering affordability and accessibility to patients.
1. EMS Sigma Pharma
EMS Sigma Pharma is one of Brazil’s leading pharmaceutical companies and has been active in the generics market since its foundation. The company holds approximately 5% of the Brazilian pharmaceutical market share. Their production capacity is estimated at over 1 billion units annually, making them a significant player in the generics space, including the production of rotigotine.
2. Aché Laboratórios Farmacêuticos
Aché Laboratórios is another major Brazilian pharmaceutical company with a strong generics portfolio. They are recognized for their commitment to quality, producing around 500 million units per year across various therapeutic classes. The company has a market share of about 4% and is actively involved in developing rotigotine generics, contributing to the accessibility of treatment options.
3. Hypera Pharma
Hypera Pharma is one of the largest pharmaceutical companies in Brazil, with a significant footprint in the generics sector. They command a market share of roughly 10% and produce over 1.5 billion units annually. Their investments in R&D have allowed them to explore the manufacture of rotigotine generics, enhancing their portfolio and market competitiveness.
4. FarmoquÃmica
FarmoquÃmica is well-known for its high-quality generics and has been in the Brazilian market for over 80 years. The company produces approximately 200 million units each year and holds roughly 3% of the market share. Their efforts in expanding their generics line include the development of rotigotine formulations, catering to an increasing patient base.
5. Medley
Medley, a subsidiary of the multinational Sanofi, is a prominent player in the generics market in Brazil. With a production capacity exceeding 450 million units annually and a market share of about 6%, Medley is involved in the production of generics, including those for treating Parkinson’s disease, such as rotigotine.
6. Prati-Donaduzzi
Prati-Donaduzzi has established itself as a significant generics manufacturer with a focus on quality and compliance. Producing around 400 million units per year, they hold a market share of approximately 2.5%. Their ongoing projects include the development of rotigotine generics, reflecting their commitment to addressing chronic disease management.
7. União QuÃmica
União QuÃmica is a well-respected name in the Brazilian pharmaceutical industry, known for its robust generics portfolio. The company produces over 300 million units annually and has a market share of around 2%. They are currently working on developing rotigotine generics to broaden their therapeutic offerings.
8. Eurofarma
Eurofarma is a leading pharmaceutical company in Brazil, recognized for its innovative approach to generics. With an annual production capacity of approximately 600 million units, Eurofarma holds a market share of about 8%. Their focus on therapeutic areas includes the development of rotigotine generics, aimed at improving patient access to treatment.
9. BR Pharma
BR Pharma is a growing player in the generics market, with a focus on affordability and quality. They produce around 250 million units annually and have captured nearly 1.5% of the market share. Their initiatives to produce rotigotine generics are part of their strategy to enhance their therapeutic portfolio.
10. Laboratório Teuto
Laboratório Teuto is known for its extensive range of generic medications and has a production capacity of over 200 million units annually. They hold a market share of about 1%. Their ongoing investment in research includes the development of rotigotine generics, which is vital for their growth strategy.
Insights
The generics market in Brazil is expected to grow significantly in the coming years, fueled by increasing healthcare demands and a push for cost-effective treatment options. According to recent analyses, the generics segment is projected to reach a market size of $18 billion by 2026, reflecting a 10% CAGR. Companies focusing on the production of rotigotine generics will likely benefit from this trend, as the demand for affordable Parkinson’s disease treatments continues to rise. Moreover, the Brazilian government’s support for generics through regulatory reforms and incentives is expected to enhance the competitive landscape, positioning Brazil as a key player in the global generics market.
Related Analysis: View Previous Industry Report
